5 High Growth Healthcare Stocks to Buy

In this article, we will take a look at the 5 high growth healthcare stocks to buy. To see more such companies, go directly to 12 High Growth Healthcare Stocks to Buy.

5. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Number of Hedge Fund Holders: 31

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)  is one of the high growth healthcare companies that is working on treatments for neuropsychiatric and neurologic disorders. In November 2022 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) posted stellar Q4 results which showed huge revenue growth. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)’s revenue in the September quarter jumped about 220% on a YoY basis to total $71.9 million, beating estimates by $5.9 million. During the period, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)’s bipolar depression treatment Caplyta saw its sales rise about 230% on a YoY basis.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)’s cash, cash equivalents, restricted cash and investment securities totaled $630.5 million as of the end of September. GAAP EPS in the period came in at -$0.57, beating estimates by $0.25.

At the end of the September quarter of 2022, 31 hedge funds had stakes in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). The total value of these stakes during this period was $493 million. The biggest stakeholder of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during this period was Israel Englander’s Millennium Management which owns an $86 million stake in the company.

TimesSquare Capital made the following comment about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in its Q3 2022 investor letter:

“Slipping by -18% was Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), which develops small molecule treatments for neurological disorders. The company reported revenues that were better than expected, though earnings were lower. There was an acceleration of sales for Caplyta, a treatment for schizophrenia and bipolar depression. However, some investors appeared concerned that as Caplyta volumes increased to a higher level that the rate of growth will slow. We view the projected growth trajectory positively, as well as Caplyta’s potential for use in other indications, so we added to our position.”